Monday, 30 November 2015

Pharma academic research - Indian patent applications published on 27th November 2015


Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at pharmaliterati@gmail.com



Invention
Application no
Inventors
Institute
Pulmonary function testing induction jacket
1596/MUM/2014A
1) Dr. Prashant Rajdeep
Department of Physiology, The M. S. University of Baroda, Vadodara, Gujarat.
Apprentice Spirometer
1597/MUM/2014A
1) Dr. Prashant Rajdeep
Department of Physiology, The M. S. University of Baroda, Vadodara, Gujarat.
Pharmaceutical composition for the fast relief and treatment of inflammation
1556/MUM/2014A
1) Shamkuwar Prashant Babarao
Government College of Pharmacy, Ratnagiri, Maharashtra. India.
Oral compositions and processes for preparing different dosage forms comprising of controlled release multi unit particulate system
1625/MUM/2014A
1) Mr. Mundada Piyush Kishor
2) Mrs. Mundada Veenu Piyush
3) Dr. (Mrs.) Sawant Krutika Khanderao
Department of Pharmacy, The M. S. University of Baroda, Vadodara, Gujarat.

Thursday, 26 November 2015

New drug approved_Ixazomib

USFDA recently approved Ixazomib, an antineoplastic agent. 

Drug name:
Ixazomib
Innovator:
Millennium Pharms
Brand name:
Ninlaro®
Chemical structure:
1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5dichlorobenzoyl) amino] acetyl]amino]-3-methylbutyl]-5-oxo-
Indications:
Ninlaro® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Dosage form:
Capsule; Oral
Strengths:
2.3mg; 3mg; 4mg

IPER_Course announcements

Institute of Pharmaceutical Education and Research, Pune founded in 1990, is India’s leading institute propagating excellence in the Pharmacy profession.

The Institute has evolved out of a much-felt, lack of comprehensive, managerial, task oriented input demanded by the rapidly growing pharmacy profession. I.P.E.R’s Pharmaceutical Management Certificate training programmes are brand new career programme evolved through the merger of practical actual experience, theoretical management principles and case studies in pharmaceutical industries, giving a never before industry orientation and training to Pharmacy education in the country. In the age of the specialist, I.P.E.R.’s tailor-made Pharmaceutical Management certificate courses suits your aptitude and interests and opens the doors for high reward placement opportunities in the Pharma Industry. The courses have been prepared by eminent personalities from pharma industry ensuring that education is relevant to the industry’s needs.

The institute announces the admissions for its courses for 2015-16.

The last date for the admissions is 30th November, 2015. The courses are as follows:

 
 
Please see: http://www.pharmadiplomas.com/images/stories/pdf/Admission-Notice-2015%20-%2016.pdf

Indian Institute of packaging course announcement


CPhI India-2015: Brace yourselves for the biggest event of the year!

The Indian Pharma fraternity: Brace yourselves for the biggest event of the year: CPhI India-2015

We had earlier posted details about CPhI India-2015 held in Mumbai from 1 - 3 December 2015 at the Bombay Convention and Exhibition Centre on our beloved blog.
But just as a refresher, please find the information and the relevant links below!  

For all those people who have not yet registered, please move it and register here:

Wednesday, 25 November 2015

Cut on heartburn pills to avoid serious side effects: Study


Doctors must prescribe heartburn and acidity pills in lowest possible doses and for shortest time to patients to ward off potential side effects, researchers warn. Called Proton pump inhibitors (PPIs), such common over-the-counter pills like omeprazole, rabeprazole and pantoprazole are taken to alleviate gastric distress from stomach acid.

"Proton pump inhibitors are associated with a number of rare but potentially serious adverse effects," wrote Dr Todd C. Lee, internal medicine specialist at McGill University Health Centre in Montreal, Quebec."These uncommon effects become highly relevant when considering the tens of millions of patients who take PPIs worldwide," he added.

Some PPIs have been associated, in observational studies, with increased risk of heart attack in patients taking the antiplatelet agent called clopidogrel.

Other adverse effects, which occur in varying frequencies, include rebound heartburn after discontinuing PPIs, malabsorption of vitamin B12, iron and magnesium, an increased risk of infection with Clostridium difficile and possible increased risk of fractures in patients receiving long-term PPI therapy.

"The review outlines the potential risks of long-term use of PPIs to help physicians and their patients understand the implications. It looks at drug interactions and noninfectious and infectious complications," the study noted.

To minimise the risk of adverse effects, the authors recommend lifestyle modifications such as limiting caffeine and alcohol which can cause gastric distress.

"We believe that PPIs should be prescribed at the lowest dose and for the shortest duration of therapy appropriate to the condition being treated," the authors concluded.

The review appeared in the Canadian Medical Association Journal.
 
Source: http://health.economictimes.indiatimes.com/news/industry/cut-on-heartburn-pills-to-avoid-serious-side-effects-study/49905807

Pfizer, IIT-Delhi collaborate for healthcare incubation

Pfizer and IIT-Delhi on Tuesday said they have launched an incubation accelerator initiative at the later's campus for Indian startup companies as well as individuals.


Christened "The Pfizer IIT-Delhi Innovation and IP Program", it comprises two components.

For innovators seeking comprehensive support to translate their healthcare ideas into patents, the programme will provide two years of residential incubation at IIT-Delhi, funding of up to Rs.50 lakh for each innovator, mentoring support from IIT-Delhi's faculty, access to infrastructure and prototyping laboratories, IP search and filing services, guidance from Pfizer's global experts, and access to venture capitalists and other industry linkages.

For innovators who already have a ready proof of concept and are seeking to obtain a patent, the programme will provide access to IP attorneys and services and cover the patent fee.

The programme will invite two rounds of proposals during 2015-2016. Call for proposals for the first round will open from November 27 until January 15, 2016.

An independent panel of subject matter experts will review and shortlist the potential incubates while the Technology Business Incubator Unit board at IIT Delhi will make the final selection of individuals and startups. 

Source: http://www.newkerala.com/news/2015/fullnews-153246.html

Tuesday, 24 November 2015

Pharma academic research - Indian patent applications published on 20th November 2015


Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at pharmaliterati@gmail.com

Invention
Application No
Inventors
Institute
Granular composition prepared using food grade saponins
2645/MUM/2014A
1) Dr. Vinita Kale
2) Kalyan Jayant Wagh
3) Dr. Abhay M. Ittadwar
Gurunanak College of Pharmacy, Nagpur
Combinatorial therapeutic regimen of antidiabetic with antihypertensive drugs
3783/MUM/2014A
1) Mr. Gokul A. Khairnar
2) Mr. Pritam B. Patil
3) Dr. Vinod J. Mokale
4) Dr. Jitendra B. Naik
North Maharashtra University
PDE4 inhibitor compounds for treating anti-depressant and anxiolytic related disorders
1290/DEL/2014A
1) Radhakrishnan Mahesh
2) Muthu Venkatesh Sudali
BITS Pilani
New α-acyl -phenylpropanoic acid derivatives as ppar- based hypolipidemic agent
1276/DEL/2014A
1) Sharma Manish
2) Malik Ruchi
Not known
Linked benzimidazole conjugates and a process for preparation thereof
1295/DEL/2014A
1) Ahmed Kamal
2) Anver Basha Shaik
3) Gajjela Bharath Kumar
4) Vangala Santhosh Reddy
CSIR
Point-of-care diagnostic kit for rapid detection of brucellosis
3183/MUM/2013A
1) Patravale; Vandana Bharat
2) Vyas; Swati Suhas
Pharmaceutical sciences and technology department, ICT Mumbai.
Modified Release Oral dosage form for the treatment of migraine
1387/MUM/2014A
1) Dr. Rajesh Harshadray Parikh
2) Bhavin Kiritbhai Patel
3) Jigar Kamabhai Desai
4) Bhavin Rameshchandra Rathod
Ramanbhai Patel College of Pharmacy, Anand, Gujarat

Pfizer to Buy Allergan in $160B Deal


2015 had already surpassed 2014 as the year with the biggest healthcare deals by value. Now, it's not even close.

"Through this combination, Pfizer will have greater financial flexibility that will facilitate our continued discovery and development of new innovative medicines for patients, direct return of capital to shareholders, and continued investment in the United States, while also enabling our pursuit of business development opportunities on a more competitive footing within our industry," said Pfizer chief Ian Read in a statement.

The makers of some of the best-selling pharmaceutical products in the world, including Viagra and Botox, are planning to join forces in an agreement that's bound to raise scrutiny from the White House and federal regulators. The Treasury Department announced last week that it would be releasing new rules to make it more difficult for pharma companies to pursue these precise types of domicile-shifting inversion mergers.

But it's unclear just how much change the government can unilaterally pursue under current tax law. The Treasury implemented a round of new anti-inversion rules last year as well, which did wind up preventing several big-name domicile-shifting deals. But other companies have still blazed forward with attempted inversions.

The current iteration of Allergan is the result of 2014's largest pharma merger, where Actavis purchased the former company for about $65 billion. 

Antitrust regulators in the U.S. and abroad will have plenty of opportunities to challenge the deal. But if push comes to shove, Pfizer and Allergan could likely divest enough interests to pass regulatory muster. The two companies had combined sales of more than $60 billion last year and have negotiated a $3.5 billion breakup fee for the merger.

During an investor call regarding the deal, Read and Saunders also said that it would take three years of audited financials before the company could make any decisions regarding a potential split-up (a move that Wall Street has encouraged Pfizer to pursue for years). That means any potential announced split-up would likely not come until about 2018.

The two CEOs also discussed drug development and pipelines during the call. Saunders praised Pfizer's rare disease and oncology platforms, while Read insisted there would be minimal disruption to Allergan's ongoing R&D efforts on drugs such as the depression therapy Naurex, ophthalmology medications, and irritable bowel syndrome drugs.

The proposed merger will undoubtedly prove controversial amid the consistent and rapid clip of healthcare consolidations over the last several years—particularly as controversies over drug pricing have caught the nation's attention and spilled over into the 2016 presidential campaign as a major issue.

Read didn't seem fazed at the prospect of being blocked by regulators during Monday's investor call. But, knowing full well about the controversy bound to dog this proposed deal, he already sent a letter to the Senate Majority Leader insisting that "Pfizer and Allergan have deep roots and are committed to the United States, and a Pfizer-Allergan combination builds even more the combined companies’ presence in the United States. We will maintain our global operational headquarters in New York City."

The letter goes on to say that there will be more than 40,000 employees of the combined company across 25 U.S. states. There will also be about 5,000 employees in Ireland.

Source: http://www.healthcaredive.com/news/pfizer-allergan-agree-to-historic-160-billion-inversion-merger/409699/

Global R & D Summit_2015


Global R&D Summit 2015, a two-day integrated conference, exhibition and award function will be a magnanimous milieu of local and global experts and institutions from industry, academia, government, bilateral/ multilateral agencies, funding organisations and associated establishments that constitute the technology-based start-up ecosystem.

Location:                     Vigyan Bhavan, New Delhi.
Dates:                          7 - 8 December, 2015
Organizers:                  FICCI and Department of Science & Technology, Government of India.
Details:                        http://www.ficcirndsummit.com/e-brochure.pdf





Monday, 23 November 2015

Pharma Transpire - 2016_ International conference on design development & practice of drugs


About the conference:
Drug Design is the inventive process of finding new therapeutics based on the knowledge of a biological target. The Phrase “Drug Design” to some extent is a misnomer, where Ligand. Design can be a more accurate scientific expression. When a new compound shows promise, its structure can be subjected to physicochemical modification with the aim to optimize its ability to target the intended site. Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research (microorganisms/animals), clinical trials (humans) and steps to obtain regulatory approval for commercialization. A Good Pharmacy Practice (GPP) is "the practice of pharmacy that responds to the needs of the people who use the pharmacists’ services to provide optimal, evidence-based care. To support this practice it is essential that there must be an established national framework of quality standards and guidelines". The objective of the present conference is to gather and share the knowledge related to the latest techniques and their progress around the globe on design, development and practice of drugs, and create a platform to raise critical issues and brainstorm for solutions. In addition, the conference provides an opportunity for researchers and future scientists to meet and network with respect to career and research advancement.

The details are as follows:
Theme:                    International conference on design development & practice of drugs

Dates:                     22nd &23rd January 2015

Organized by:        Creative educational society's college of pharmacy; Non-destructive biomed pharma research centre, Universiti Teknologi Mara; Integrative Pharmacogenomics Institute.

Location:                   Chinnatekure, Kurnool, Andhra Pradesh, India.

Details available at:  http://www.cescopseminar.org/

Call for abstract is now open:
30 December 2015     Deadline for abstract submission
30 November 2015     Conditional acceptance of abstracts
2 January 2016            Notification of abstract acceptance for oral presentation
2 January 2016            Notification of abstract acceptance for poster presentation
30 December 2015     Deadline for early-bird registration

Saturday, 21 November 2015

AstraZeneca and Sanofi to exchange compounds


In an unusual move AstraZeneca and Sanofi will exchange 210,000 compounds in order to boost their libraries and help launch more drug discovery programmes.

The companies have selected the compounds to exchange based on differences from those in their own libraries. Each company will receive sufficient quantities to enable high throughput screening for several years to determine whether they are active against specific biological targets AZ and Sanofi will also share chemical structures and synthetic procedures to facilitate the use of the compounds.

Each company can investigate the compounds it receives without restrictions on disease areas.

“This is a highly innovative agreement which speaks to our open innovation approach,” said Mene Pangalos, executive vice president of innovative medicines and early development at AstraZeneca.  “We’ve worked hard to enrich our compound library in recent years and this exchange, which is by far the largest we have achieved, enables us to significantly increase its diversity. Most importantly, it will accelerate our ability to identify unique starting points that could become new medicines for patients.”

Elias Zerhouni, president of global R&D at Sanofi added: “Sanofi is committed to open innovation in our R&D platforms because we recognise that collaboration is the foundation of every medical breakthrough. We are happy to partner with other companies if it will speed the discovery of new life-saving or life-enhancing therapies for patients.” There are no payments associated with the compound exchange.

Three more partnerships for AZ
AZ has also announced three new partnerships aimed at helping its new MRC UK Centre for Lead Discovery, which will be located within the company’s new global R&D centre at the Cambridge Biomedical Campus, in the search for novel small molecule medicines. 

The first is a three-year agreement with HighRes Biosolutions, a global provider of automated robotic systems to the life sciences industry, to develop next generation, intelligent robots for the high throughput screening of compounds.

AZ has also announced a strategic partnership to use the energy of sound waves to dispense compounds directly from individual storage tubes into well plates for testing. This comprises fully-automated liquid handling by Labcyte, automated liquid storage systems by Brooks Automation, and a co-developed acoustic sample storage tube.

Finally, the company is hoping that a five-year collaboration with Genedata, a provider of advanced software solutions for drug discovery and life science research will speed data sharing with partners.

Read more at: 

Zydus launches diabetes drug at Rs 7/day, 1/6th of MNCs' price


Ahmedabad-based Zydus Cadila is launching an anti-diabetic drug, teneligliptin, at an aggressive price of Rs 7 per day, almost 1/6th the price at which the established gliptins by MNCs are sold. The company said the pricing of the "breakthrough' drug, Tenglyn, is aimed at "making it affordable and accessible to diabetic patients".

The drug is priced one-third of the price charged by other domestic companies, including Glenmark Pharma and Ajanta, which are selling the same drug, teneligliptin, for around Rs 20 for a day's therapy. Experts say with competition, prices of these drugs could come down later, but as of now companies are "waiting and watching" the development.

Teneligliptin, a third-generation new oral anti-diabetic drug, was first launched by Glenmark in June, priced aggressively at nearly Rs 20 for a day's therapy (Rs 7,263 per year). As against this, all gliptins being sold in the market are priced around Rs 45 for a day's therapy, taking the cost of treatment for patients to nearly Rs 16,500 per year. With the Zydus launch, diabetics who are prescribed the gliptin can expect to make more savings. The company has been able to offer the drug at the "affordable price because of its indigenous cost-effective API (raw material) it uses", a Zydus official told TOI.

Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management, the company said. Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycemia, GI side-effects, lactic acidosis, weight gain, CV risks, which pose a major challenge in the treatment of diabetes.

The economic burden of diabetes is high in India as most patients pay out of pocket, and due to lack of medical reimbursement. Worse, the cost of treatment also includes consultation, investigations, drugs, monitoring, complications, while the complications related to the disease may increase it substantially. However, since the molecule has not been used extensively right now across the world, it's safety data needs more scrutiny, doctors say.

Overall, the oral anti-diabetic market in which teneligliptin is the new entrant, is valued at approximately Rs 5,000 crore, increasing at 20% per annum, while the gliptin family is at Rs 1,200 crore, growing at 25%.

TOI: http://timesofindia.indiatimes.com/business/india-business/Zydus-launches-diabetes-drug-at-Rs-7/day-1/6th-of-MNCs-price/articleshow/49867211.cms

Friday, 20 November 2015

Antibiotic awareness resistance


Who Health Organization is celebrating the first World Antibiotic Awareness Week from 16 to 22 November 2015. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. 



Further readings on antibiotics on Pharma literati blog:

1. Research Reveals How Antibiotics Work


2. India is the World's antibiotic popping capital